

Please type a plus sign (+) inside this box → ☐

PTO SB 08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A, PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	Continuation of 09/257,130
Filing Date	
First Named Inventor	Raymond F. Schinazi, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	EMU 2000 18085.105232

Sheet **1** of **3**

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clms, Lns, Where Relevant Passages/Relevant Figs Appear
		Number	Kind Code (if known)			
h	AA	6,232,300		Schinazi et al.	05-15-2001	
	AB	5,905,070		Schinazi et al.	05-18-1999	
	AC	5,886,162		Kalman et al.	03-23-1999	
	AD	5,703,058		Schinazi et al.	12-30-1997	
	AE	5,587,362		Chu et al.	12-24-1996	
	AF	5,567,688		Chu et al.	10-22-1996	
	AG	5,565,438		Chu et al.	10-15-1996	
	AH	5,512,671		Piantodosi et al.	04-30-1996	
	AI	5,446,029		Eriksson et al.	08-29-1995	
	AJ	5,426,183		Kjell et al.	06-20-1995	
	AK	5,424,416		Jones et al.	06-13-1995	
	AL	5,246,924		Fox et al.	09-21-1993	
	AM	5,128,458		Montgomery et al.	07-09-1992	
	AN	5,034,518		Montgomery et al.	07-23-1991	
	AO	4,666,892		Fox et al.	05-19-1987	
	AP	4,625,020		Brundidge et al.	11-25-1986	
	AQ	4,336,381		Nagata et al.	06-22-1982	
	AR	4,211,773		Lopez et al.	07-08-1980	
	AS	09/435,268 6,407,071		Schinazi et al.	6-18-02	
	AT	09/435,261		Gosselin et al.		

Examiner Signature

[Handwritten Signature]


Date Considered

7/24/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box → 

PTO SB 08A (08-00)






Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	09/257,130
				Filing Date	
				First Named Inventor	Raymond F. Schinazi et al.
				Group Art Unit	
Sheet	2	of	3	Attorney Docket Number	EMU20000. 18085. 105232

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document DD-MM-YYYY	Country	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
2	BA	WO	98/18430					
	BB	WO	97/37993					
	BC	WO	97/28177					
	BD	WO	96/40164					
	BE	WO	96/22778					
	BF	WO	92/14743					
	BG	EP	0 409227					
	BH	EP	0 352 248					
M	BI	EP	0 316017					

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	BJ	BALAKRISHNA, et al., "Inhibition of Hepatitis B. Virus by a Novel L-Nucleoside, 2'-Fluoro-5-Menthyl- -L- arabinofuranosyl Uracil," <i>Antimicrobial Agents and Chemotherapy</i> , Feb. 1996, pages 380-356	
	BK	BORTHWICK, et al., "Synthesis and Enzymatic Resolution of Carbocyclic 2'-Ara-fluoro-Guanosine; A Potent New Anti-Herpetic Agent," <i>J. Chem Soc., Chem. Commun.</i> 1988.	
	BL	CHENG, et al., <i>Journal of Biological Chemistry</i> , Volume 267(20), pp. 13938-13942 (1992).	
	BM	CHU, et al., "Use of 2'-Fluoro-5-methyl- -L-arabinofuranosyluracil as a Novel Antiviral Agent for Hepatitis B. Virus and Epstein-Barr Virus" <i>Antimicrobial Agents and Chemotherapy</i> , April 1995 pages 979-981.	

Examiner Signature		Date Considered	7/24/02
-----------------------	---	--------------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Submitted for form 1449/PTO				Complete if Known	
				Application Number	09/257,130
				Filing Date	
				First Named Inventor	Raymond F. Schinazi et al.
				Group Art Unit	
Sheet	3	of	3	Attorney Docket Number	EMU20000. 18085. 105232

u	CA	FURMAN, et al., "The Anti-Hepatitis B. Virus Activities, Cytotoxicities, and Anabolic Profiles of the (-) and (+) Enantiomers of cis-5-Fluoro-1[2-(Hydroxymethyl)-1, 3-oxathiolane-5-yl]-Cytosine" <i>Antimicrobial Agents and Chemotherapy</i> , December 1992, pp. 2686-2692.	
u	CB	MACHIDA, H., et al., <i>Antiviral Research</i> , 39 (1998) p.129-137	
u	CC	MARQUEZ, V.E., et al., <i>Nucleosides & Nucleotides</i> , 14(3-5), 555558 (1995)	
u	CD	MARTIN, et al., "Synthesis and Antiviral Activity of Monofluoro and Difluoro Analogues of Pyrimidine Deoxyribonucleosides against Human Immunodeficiency Virus (HIV-1), <i>J. Med. Chem.</i> 1990, 33, 2137-2145.	
u	CE	SCHINAZI, et al., Mutations in retroviral genes associated with drug resistance, <i>International Antiviral News</i> , 1997.	
u	CF	SCHINAZI, et al., "Selective Inhibition of Human Immunodeficiency viruses by Racemates and Enantiomers of cis-5-Fluoro-1-2[Hydroxymethyl)-1, 3-Oxathiolane-5-yl]Cytosine" <i>Antimicrobial Agents and Chemotherapy</i> , November 1992, pp. 2423-2431.	
u	CG	SIDDIQUI MA et al., <i>Tetrahed. Letters</i> , vol. 39 no. 13 26 March 1998.	
u	CH	STERZYCKI, et al., "Synthesis and Anti-HIV Activity of Several 2'-Fluoro-Containing Pyrimidine Nucleosides," <i>J. Med. Chem.</i> 1990.	
u	CI	SU, T.S., et al., "Sythesis and Antiviral Effects of Several 1-(2-Deoxy-2-fluoro-B-D-arabinofuranosyl)-5-alkyluracils. Some Structure-Activity Relationships," <i>J. Med. Chem.</i> , 1986, 29, 151-154.	
u	CJ	TOYOTA, A., et al., <i>Tetrahedron</i> vol 51, no. 32, pp. 8783-8798, 1995.	
u	CK	WANTANABE, et al., "Synthesis and Anti-HIV Activity of 2'-"Up"-Fluoro Analogues of Active Anti-Aids Nucleosides 3'-Azido-3'-deoxythymidine (AZT) and 2', 3'-dideoxycytidine (DDC)," <i>J. Med. Chem.</i> 1990, 33, 2145-2150.	
	CL	YOAHMURA, Y., et al., <i>J. Org. Chem.</i> , 1999, 64, 7912-7920.	

Examiner Signature		Date Considered	7/24/02
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231